Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on MK-2870 for Patients with Endometrial Cancer After Platinum and Immunotherapy Treatment

Fast replyRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of a new treatment for endometrial cancer, a type of cancer that begins in the lining of the uterus. The treatment being tested is called MK-2870, which is a type of medication known as a monoclonal antibody. Monoclonal antibodies are proteins designed to target specific cells in the body, such as cancer cells. In this study, MK-2870 will be compared to other treatments chosen by doctors, which may include various medications that patients have previously received, such as chemotherapy and immunotherapy.

The purpose of the study is to compare the effectiveness and safety of MK-2870 with other treatments. Participants in the study will be randomly assigned to receive either MK-2870 or a treatment chosen by their doctor. The study will monitor how long participants live without their cancer getting worse and their overall survival. Participants will receive the treatment through an intravenous infusion, which means the medication is given directly into a vein. The study will also look at how well the cancer responds to the treatment and any side effects that may occur.

Throughout the study, participants will have regular check-ups and tests to monitor their health and the progress of their cancer. These tests may include imaging scans to see how the cancer is responding to the treatment. The study aims to provide valuable information about the potential benefits and risks of MK-2870 for people with endometrial cancer who have already received other treatments. The study is expected to continue for several years to gather comprehensive data on the treatment's effectiveness and safety.

The research process

The trial runs in 8 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, the participant will be informed about the trial's purpose, which is to compare the effectiveness and safety of MK-2870 with other treatments chosen by the physician for individuals with endometrial cancer who have previously received platinum-based chemotherapy and immunotherapy.

  2. Step 2

    Initial assessment

    An initial assessment will be conducted to confirm the diagnosis of endometrial carcinoma or carcinosarcoma. This includes ensuring the disease is visible on imaging tests, either measurable or non-measurable, as per specific criteria.

  3. Step 3

    Treatment allocation

    Participants will be randomly assigned to receive either MK-2870 or a treatment chosen by the physician. MK-2870 is administered as a powder for solution for injection through an intravenous infusion.

  4. Step 4

    Treatment administration

    The treatment will be administered according to the assigned group. If receiving MK-2870, the participant will undergo regular intravenous infusions. The frequency and duration of these infusions will be determined by the study protocol.

  5. Step 5

    Monitoring and evaluation

    Throughout the trial, participants will be monitored for progression-free survival and overall survival. This involves regular assessments using imaging tests to evaluate the response to treatment.

  6. Step 6

    Adverse events monitoring

    Participants will be observed for any adverse events or side effects. The number of participants experiencing adverse events and those who discontinue the study due to these events will be recorded.

  7. Step 7

    Quality of life assessment

    Changes in the participant's global health status and quality of life will be assessed using a standardized questionnaire. This will help evaluate the impact of the treatment on daily living.

  8. Step 8

    Completion of the study

    The study is expected to conclude by January 10, 2028. Participants will receive a final evaluation to assess the overall outcomes of the treatment.

Who can join the trial?

5 criteria

  • The patient must have a confirmed diagnosis of **endometrial carcinoma** or **carcinosarcoma**. This means that a doctor has determined that the patient has one of these types of cancer.
  • The patient must have a disease that can be seen on medical imaging tests. This disease can be either measurable or non-measurable according to specific guidelines used by doctors.
  • The patient must have previously received **platinum-based chemotherapy**. This is a type of cancer treatment that uses drugs containing the metal platinum.
  • The patient must have also received therapy targeting **programmed cell death 1 protein (PD-1)** or **programmed cell death ligand 1 (PD-L1)**. These are treatments that help the immune system fight cancer.
  • The study is open to female patients only.

Who cannot join the trial?

3 criteria

  • Patients who have a different type of cancer than endometrial cancer cannot participate. Endometrial cancer is a type of cancer that starts in the lining of the uterus.
  • Only female patients are eligible for this study. Male patients cannot participate.
  • Patients who are part of a vulnerable population are not eligible. A vulnerable population includes groups of people who may have a higher risk of harm or exploitation, such as children, pregnant women, or those with certain disabilities.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • MK-2870

    is an investigational medication being studied for its effectiveness and safety in treating endometrial cancer. This medication is being tested as a monotherapy, meaning it is used alone without combining it with other treatments. The trial aims to determine how well MK-2870 works in prolonging the time patients live without their cancer getting worse and in improving overall survival rates. This study is particularly focused on patients who have already received platinum-based chemotherapy and immunotherapy.

  • Treatment of Physician's Choice (TPC)

    refers to a range of standard treatments that a doctor may choose based on the patient's specific condition and medical history. In this trial, TPC serves as a comparison to MK-2870 to evaluate which option provides better outcomes for patients with endometrial cancer. The specific treatments included in TPC can vary, as they are tailored to each patient's needs and the physician's clinical judgment.

What is already known about the treatment

MK-2870 – This medication is administered as a monotherapy for endometrial cancer, particularly in patients who have previously undergone platinum-based chemotherapy and immunotherapy. Currently, MK-2870 is being evaluated in a Phase 3 clinical trial to assess its effectiveness and safety compared to other treatments chosen by physicians. The main therapeutic indication for MK-2870 is endometrial cancer, and it is being studied for its potential to improve progression-free survival and overall survival in patients. The mechanism of action at the molecular level involves targeting specific pathways that contribute to cancer cell growth and survival, although detailed molecular interactions are still under investigation. MK-2870 is classified pharmacologically as an investigational cancer therapy, reflecting its current status in medical research.

Investigated diseases

Endometrial cancer – This is a type of cancer that begins in the lining of the uterus, known as the endometrium. It is most commonly diagnosed in women who have gone through menopause. The disease often presents with symptoms such as abnormal vaginal bleeding or discharge. As it progresses, the cancer can invade the muscular layer of the uterus and may spread to other parts of the body. The progression of endometrial cancer can vary, with some cases remaining localized while others may metastasize. Early detection is crucial for managing the disease effectively.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2023-504816-14-00Protocol codeMK-2870-005Estimated enrolment710 patientsSponsorMerck Sharp & Dohme LLC

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.